Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2010, Article ID 473453, 11 pages
http://dx.doi.org/10.1155/2010/473453
Research Article

Long-Term Follow-Up of HLA-A2+ Patients with High-Risk, Hormone-Sensitive Prostate Cancer Vaccinated with the Prostate Specific Antigen Peptide Homologue (PSA146-154)

1Section of Hematology and Oncology, Department of Medicine, College of Medicine Research Building, University of Illinois at Chicago, 909 South Wolcott Avenue, Chicago, IL 60612, USA
2Department of Epidemiology and Biostatistics, University of Illinois at Chicago, Chicago, IL 60612, USA
3Proteomics Core Research Facility, Rush University Medical Center, Chicago, IL 60612, USA

Received 1 July 2010; Revised 7 December 2010; Accepted 14 December 2010

Academic Editor: Bartholomew Akanmori

Copyright © 2010 Supriya Perambakam et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Twenty-eight HLA-A2+ patients with high-risk, locally advanced or metastatic, hormone-sensitive prostate cancer were immunized with a peptide homologue of prostate-specific antigen, PSA146-154, between July 2002 and September 2004 and monitored for clinical and immune responses. Fifty percent of the patients developed strong PSA146-154-peptide-specific delayed-type hypersensitivity skin responses, tetramer and/or IFN-γ responses within one year. Thirteen patients had stable or declining serum levels of PSA one year post-vaccination. A decreased risk of biochemical progression was observed in patients who developed augmented tetramer responses at six months compared to pre-vaccination levels ( ). Thirteen patients have died while 15 patients remain alive with a mean overall survival of 60 months (95% CI, 51 to 68 months) per Kaplan-Meier analysis. A trend towards greater overall survival was detected in men with high-risk, hormone-sensitive CaP who developed specific T-cell immunity following vaccination with PSA146-154 peptide.